Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor for myocardial injury reduction in stable coronary artery disease with high-risk plaque
2014-000952-26Phase 2Completed
- Sponsor
- University of Edinburgh
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ticagrelor in coronary arteriosclerosis, sponsored by University of Edinburgh. Primary endpoint: Plasma high sensitivity cardiac troponin I concentration in patients with coronary 18F-fluoride uptake. Started Jul 2014; status: completed.
02
Drugs
ticagrelor
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2014-000952-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000952-26.